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Abstract
One of the most revealing parts of the human body is the eye. In fact, systemic conditions and diseases are commonly manifested
in the eye and display pathology that reflect disorders. An example of a chorioretinal vascular condition that can present itself in
the eye is diabetes mellitus, which if left uncontrolled can damage the eyes and a person’s vision. Age related macular degeneration
is specific to the eye, potentially leading to irreversible loss of central vision. Intravitreal injections containing vascular endothelial
growth factor inhibiting agents appear to be the leading lines of defense against diabetic retinopathy and macular degeneration
progression, helping to reduce both the pathological and visual manifestations of these chorioretinal vascular diseases.
Background
Diabetes is the fourth leading cause of health complications, making many people susceptible to diabetic retinopathy. In fact, the prevalence of diabetes is expected
to increase by 7.7% by 2030, leaving many people at risk
(Abbas et al., 2017). Age related macular degeneration is
another neovascular condition of the eye which can reduce visual acuity to 20/800 in a patient’s better eye by
60%, resembling a patient who “is bedridden with a catastrophic stroke” (Folk & Stone, 2012). These diseases are
capable of impairing the daily functioning of a patient if
they are not treated and monitored. Most ocular diseases can be identified with a dilated eye exam. Treatments
with delivery of vascular endothelial growth factor inhibitors to the retina via intravitreal injection has gradually
become the first line of treatment for ocular conditions
such as diabetic retinopathy and macular degeneration.
Pan-retinal photocoagulation (PRP) is a laser treatment
that can also be used in controlling these conditions and
preventing the progression of vision loss. Research is currently being done on both of these methods in an effort
to determine their use in ocular disease.
Hypothesis
In most circumstances, vascular endothelial growth factor
inhibiting medications can be implemented in a treatment
plan to alleviate both the visual complaints and the pathological findings associated with chorioretinal vascular
conditions. In some cases, however, this treatment option
may not be appropriate due to potential risks and another treatment may be indicated.
Methods
Research for this paper was conducted with the use of ProQuest, EBSCO, and Pub-Med databases. Figures used throughout include corresponding sources from research articles.
Diagnostic Methods
Conditions such as age-related macular degeneration
and diabetic retinopathy can be diagnosed with a proper exam. Ophthalmic tropicamide, a mydriatic, is used in
order to give the clinician a proper view of the fundus.

Imaging methods such as optical coherence tomography
(OCT), fluorescein angiography, and wide field fundus
imaging may also be used for future comparison during
treatment. Diagnostic guidelines have been established to
aid in classifying the type and severity of ocular disease.
Findings, diagnostic methods, visual complaints, and prognosis of these conditions will be discussed in the following
sections. Popular treatment options will also be outlined.
Diabetic Retinopathy
Diabetic retinopathy (DMR) is a complication resulting
from diabetes mellitus Type 1 or 2. It appears to be one
of the leading causes of blindness in patients aged 20-65
(Stewart, 2012). Currently, 336 million people suffer from
diabetes and are therefore at risk of developing diabetic
retinopathy, otherwise known as DMR (Abbas et al., 2017).
Diabetic damage to the eye is a result of macular edema,
which in more advanced cases, can lead to intraocular
bleeding, detachments of the retina, macular ischemia, and
retinal neovascularization. Possible risk factors for DMR
include hyperglycemia, elevated blood pressure, and elevated serum levels (Buffolino & Park, 2019). Patients can
usually control risk factors with lifestyle modifications
including diet and exercise, yet it is important to note
that specific patient demographics can predispose people
to diabetic retinopathy.
Firstly, individuals diagnosed with diabetes at an earlier
age tend to be more vulnerable to developing the condition. DMR becomes more prevalent as the age of diabetes
onset is younger. “What is hitherto unknown is whether
the increased prevalence of complications associated with
early-onset disease is simply a consequence of the longer duration of disease, a consequence of a more severe
metabolic phenotype, or in fact something specific to the
diabetic milieu in younger patients that makes tissues more
inherently susceptible to hyperglycemic damage” (Wong
et al., 2008). Long-term exposure to elevated blood glucose levels seems to lead to oxidative stress on the eyes
(Stewart, 2012). By the same token, retinopathy is not
common in the first five years of a Type 1 diabetes onset,
and diabetic retinopathy tends to be present after 20 years
of having Type 2 diabetes (Cook et al., 2008).
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Secondly, in addition to patient age, ethnicity is also
associated with DMR. African Americans, Hispanics, and
South Asians are especially prone to diabetic retinopathy.
African Americans seemingly have reduced glycemic control, which can lead to retinal complications due to higher
A1C values. The internationally recognized mark differentiating safe and unsafe A1C values is 7% (Long et al.,
2017). A study showed that over a six-year period, 72%
of African Americans with Type 1 diabetes mellitus developed retinopathy (Buffolino & Park, 2019). Furthermore,
the combination of male sex, African American ethnicity,
duration of standing diagnosis, and value of hemoglobin
A1C, were “positively associated with retinopathy severity” (Long et al., 2017).
Before any signs of diabetic damage appear on the
retina, choroidal vessels may constrict due to hypoxia
and vascular changes can develop. Furthermore, it is important to note that in the early stages of damage to the
retina, the patient may not be able to discern changes
in visual acuity; the condition is usually diagnosed in a
later stage of diabetic retinopathy (Wang & Tao, 2019).
About 50% of patients with diabetes do not come for
yearly screening visits (Buffolino & Park, 2019). The first
markers of diabetic damage in the eye are the results of
swelling and leakage of blood vessels because of poorly
controlled blood sugar levels. The natural synthesis of
vascular endothelial growth factors (VEGF) results in
the disruption of the blood-retina barrier that leads to
the spread of serum proteins leading to edema (Stewart,
2012). Bleeding near the macula can noticeably blur the
patient’s vision. According to Mayo Clinic’s webpage on
diabetic retinopathy (n.d.), the patient may also complain
of fluctuating vision. This can occur because of uncontrolled blood sugar levels that cause the lens to swell and
alter the refraction of light in the eye.Two other common
visual complaints are impaired color vision and floaters
(Vien, n.d.). Over time, the body may begin to generate
new blood vessels in order to properly supply the eye
with oxygen, which severely impacts the patient’s vision
and everyday functioning. Other lesions associated with
diabetic retinopathy such as microaneurysms, hemorrhages, cotton wool spots, and hard exudates can be seen.
Diagnosis and Prognosis of Diabetic Retinopathy
Diabetic retinopathy is classified into either proliferative
or nonproliferative diabetic retinopathy (PDR/NPDR)
and then further broken down into mild, moderate, and
severe. This classification considers the degree of damage
present on the retina. The job of the clinician is not an
easy one to classify the stage of diabetic retinopathy.With
the help of wide field fundus imaging, the ophthalmologist
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is able to document and compare any changes to the appearance of the retina. The wide field images below can
demonstrate the classifications of diabetic damage to the
retina based on any associated findings.
Additionally, optical coherence tomography (OCT) is
used to provide cross-sectional scans of the retina which
can also help in determining the presence and degree of
edema or cotton wool spots. Layers of the retina such as
the RPE and choroid may also be altered.
Age-Related Macular Degeneration
Age related macular degeneration (AMD) is the most
common cause of blindness in patients older than age 65.
In industrialized countries, blindness due to AMD had a
reported 1.47% prevalence and affected 1.75 million people in the United States alone (Eng, et al., 2019).The deposition of yellow, extracellular material underneath the
retinal pigment epithelium that form drusen, indicative of
photoreceptor cells that are degenerating is a key component of AMD (Virgili et al., 2015). The RPE must reuse
materials in order to help revitalize photoreceptors. A
defect in the cycle suggests the poor quality of enzymes
that are responsible for breaking down those materials
(Sarks et al., 1994), leading to degeneration of the RPE
as drusen evolve into geographic atrophy. Extracellular
deposits or atrophy of the RPE near the retina can lead
to significant loss of central vision. As the drusen degenerate, they give a white appearance to the retina with
“irregular margins and foci of calcification before disappearing to leave a focal patch of atrophy” (Sarks et al.,
1994). Most patients complain of blurred or distorted
vision or a scotoma (Cook et al., 2008). Risk factors for
AMD include smoking, hyperlipidemia, and hypertension.
Age-related macular degeneration is also strongly tied to
a genetic predisposition to the point that children and siblings of patients with AMD are automatically considered
suspects for the condition. Many sources rank genetics
as an important contributor to the likelihood of developing age-related macular degeneration. Various studies
show that people of African descent have a reduced risk
for AMD, than does the Caucasian population (Delcourt,
n.d.). Smoking increases the risk of AMD as well.
Although much about AMD and its pathogenesis is still
unknown, studies show “that the largest single genetic
factor contributing to AMD is a variant of codon 402 in
the gene encoding complement…[that] strongly supports
the long-held belief that the immune system is an important contributor to AMD” (Folk & Stone, 2012). In some
observed cases of AMD, inflammatory mediators and
other molecules have been found at the macula, indicating
that there is indeed a connection between the condition
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and inflammation. Furthermore, the release of excess activated macrophages in chronic inflammatory diseases is
linked to cellular damage at the macula. Electron microscopy and immunohistochemistry methods were used to
detect the presence of inflammatory biomarkers at sites
of atrophy and neovascularization in patients with AMD
(Cachulo & Costa, 2017).
Prognosis and Classification of AMD
Age-related macular degeneration is diagnosed with
a dilated retinal examination. Evaluating a case of AMD
requires paying attention to changes at or near the macula. Age-related macular degeneration begins with the
dry form, characterized by the presentation of drusen.
Number, size, and location of drusen are helpful in determining the progression of the condition. Additionally,
drusen with indistinct borders seem to be indicative of
the advancement of AMD (Cachulo & Costa, 2017).
As AMD progresses, the retinal pigment epithelium
layer begins to show signs of atrophy. A case of AMD is
characterized as wet or neovascular once new blood vessels begin to grow over or underneath the RPE (Folk &
Stone, 2012). The generalized term “late AMD” refers to
two specific presentations on the macula with exudates
which can either be geographic atrophy or vascular AMD.
Progression from dry to wet AMD occurs for 15% of
patients complaining of severe loss of central vision and
presenting with geographic atrophy that develops (Eng et
al., 2019). Patients may notice visual distortion of straight
lines. Ten percent of patients with AMD suffer from this
more advanced form. More than 200,000 patients in the
United States alone are diagnosed per year, accounting
for 90% of all severe vision loss (Stewart, 2012). In a large
study done, “the prevalence of large drusen increased
from about 1.5% in Caucasians aged 40-49 years, to more
than 25% in those aged 80 years or more” (Delcourt,
n.d.). This statistic is important to consider because it
indicates that Caucasians appear to be more at risk for
developing AMD than people of other demographics such
as Hispanic American, African American, and Chinese
(Delcourt, n.d.). Of course, as the name of the condition
suggests, the likelihood of developing AMD increases exponentially with age.
VEGF in Ophthalmology
Angiogenesis is a process that can be both lifesaving
and necessary, yet in some cases can be detrimental.
Throughout the body, the natural process for generating
new blood vessels is crucial for maintenance related to
growth (embryonic or otherwise) and repair. Yet in circumstances of hypoxia and inflammation, it allows the

growth of tumors and is linked to the destruction of tissue (Stewart, 2012). Angiogenesis is also important when
neovascularization is required such as after myocardial
infarction. However, in ophthalmic cases, the generation
of new blood vessels can lead to hyperpermeability that
can harm vision by leading to retinal detachments and
edema between the retinal layers. The primary molecule
that is associated with angiogenesis is vascular endothelial
growth factor. “Within the posterior segment of the eye,
VEGF is produced by retinal pigment epithelial cells, neurons, glial cells, endothelial cells, ganglion cells, Muller cells,
and smooth muscle cells” (Stewart, 2012). The primary
cells of interest leading to the harms from AMD and DMR
however, are vascular endothelial cells. Generally, the synthesis of VEGF is triggered by tissue hypoxia that can either be caused by “primary vascular occlusive disease or
anaerobic tumor metabolism” (Stewart, 2012).The mechanism leading to the proliferation of vessels is complex
but it results in mitosis and swelling of the endothelial
cells, as well as vasodilation, helping new blood vessels
develop. Specifically, VEGF works to encourage growth
along the endothelial cells and dissolve the spaces between them, leading to the breakdown of the blood-retinal barrier that makes capillaries leak and new, potentially
detrimental, blood vessels form (Stewart, 2012). VEGF-A,
a subfactor of this molecule, is linked to growth and
permeability of newly-developing blood vessels. VEGF
inhibitors block the receptors that natural VEGF would
bind to, preventing angiogenesis. “Long-term blockade of
VEGF-A [receptor] causes shrinkage and maturing of the
vessels so that they no longer leak. The accumulation of
fluid within and beneath the retina dissolves, and the photoreceptors reattach to the underlying retinal pigment
epithelium” (Folk & Stone, 2012). By using a medication
that reduces the permeability of the retinal vessels and
stopping their growth, leakage is also reduced, preventing
swelling in order to bring the patient’s visual acuity back
to baseline (Folk & Stone, 2012). It is interesting to note
that these drugs are capable of resolving findings associated with two very different conditions in that one is
systemic and can target multiple parts of the body, while
the other is localized in the eye.
VEGF Inhibitors: A Comparison
Although all VEGF inhibitors prevent neovascularization,
there are several subclasses of this drug. Their generic
names aflibercept, bevacizumab, and ranibizumab will be
used throughout this paper (Folk & Stone, 2012). The efficacy of the medications as they compare to each other
is still being studied.
Bevacizumab received approval from the Food and
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Drug Administration for the treatment of colon cancer.
Bevacizumab also binds to VEGF-A, which led clinicians to
think that the drug may also be effective in treating neovascularization and exudates on the retina.Although there
is no FDA approval for its intravitreal use, bevacizumab is
proving itself effective (Folk & Stone, 2012). When compared to other medications in its class, bevacizumab has
a longer half-life. One dose of the drug can reduce levels
of natural VEGF in the blood by 117 times in just one day
and when measured after one month, still maintained a
four-fold reduction (Stewart, 2012). Furthermore, many
clinicians recommend this drug because of its vast difference in cost compared to others. Being prepared in
larger doses than is necessary for the eye means that the
medication can be divided for multiple doses (1.25 mg.
on average), reducing the cost even further. Whereas a
dose of ranibizumab costs $2000, bevacizumab, although
regarded as off label therapy, costs $75 per treatment
(Folk & Stone, 2012).
Ranibizumab was developed specifically for use in the
eye by fragmenting the bevacizumab molecule for higher
affinity by five to twenty times more than bevacizumab
(Stewart, 2012). A study looking at regular monthly treatment with ranibizumab shows that the first five years of
treatment produce the best results in terms of visual acuity, but then results seem to approach baseline levels over
time thereafter (Nishikawa et al., 2019). For treatment with
ranibizumab, the MARINA study attempted to determine
effective dosage of the medication. At random, 716 patients with neovascular AMD were treated with monthly
0.3mg or 0.5mg injections of the drug, or sham treatment
for 24 months. Results showed that 92% of patients that
were treated with 0.3mg of ranibizumab and 90% treated
with 0.5mg lost less than 15 letters when being tested for
changes in visual acuity. Furthermore, 26.1% of patients
that were treated with 0.3mg and 33.3% with 0.5mg treatment had a 15-letter improvement or greater.
When aflibercept is compared to the other drugs, its
increased binding affinity to VEGF-A receptors combined
with its larger molecular size allows for a higher efficacy
and hence, less frequent treatment. When used on a twomonth basis after three monthly consecutive loading doses,
results compared to monthly treatment with ranibizumab
(Stewart, 2012). Patients with neovascular AMD who were
treated with aflibercept intraocular injections were able to
sustain improved vision for four years. Even though after
one year some regression was present, 94.5% of patients
still had improved vision. “Thus, visual gain [of aflibercept]
in the first year is generally favorable, but long-term outcome is not as promising” (Nishikawa et al., 2019).
Conclusively, visual acuity was shown to improve with all
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three classes of treatment, but specific data was shown by
a study conducted by DRCR.net in which 600 Americans
with diabetic edema participated. The average age was 61
and most people had diabetes for over 15 years. Visual
acuity before the study was 20/32 or worse and patients
were administered either of the three drugs at random
and monitored on a monthly basis in the first year of the
study. When comparing the visual acuity of patients after
treatment, those on aflibercept for two years were able
to read 3.5 more lines compared to ranibizumab patients
who read 3, and bevacizumab patients read 2.5 (Wells,
2016). Aflibercept showed better efficacy after the oneand two-year mark. “By two years, 41 percent of participants in the aflibercept group received laser treatment
to treat their macular edema, compared with 64 percent
of participants in the bevacizumab group and 52 percent
in the ranibizumab group.” Ultimately, with treatment involving any of the three drugs, visual acuity was improved
to 20/32 and 20/40. There were even studies showing the
efficacy of bevacizumab in improving patients’ visual acuity from 20/235 to 20/172.The results of the study suggest
that there is a slight difference between the frequencies
at which the drug must be readministered depending on
the specific type of medication chosen. According to the
DRCR study done, there was no significance to using one
medication over another for treatment of mild macular
edema when visual acuity is 20/40 or better. However,
in cases of 20/50 or worse vision it has been shown that
Eylea (aflibercept) performed better than ranibizumab
and bevacizumab (Wells, 2016).
Risks
Although this modality of treatment is usually the first
line of defense against further damage to the retina, existing risks should be considered. Firstly, for all the subclasses of intravitreal injections used for treating chorioretinal
disorders, the risk for eye infection and inflammation is
the same. These are consequences of the administration
and not the drug itself (Wells, 2016). Injection into the
vitreous chamber also raises the risk for endophthalmitis, retinal tear or detachment at the area of injection,
and vitreous hemorrhage because of penetrative trauma
(Pershing et al., 2013). These risks must be kept in mind
when developing a treatment plan for a patient suffering
with other kinds of ocular disease as well. Furthermore,
because additional fluid is added to the vitreous cavity
when the medication is given, an elevation in intraocular
pressure from increased volume in the eye can result.
A study was done spanning academic centers Stanford
University Hospital & Clinics and Mayo Clinic. Patients
who received anti-VEGF injections between January 1,
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2006 and December 31, 2010 participated in order to
determine the relationship between administration of
the drug and intraocular pressure elevation taking place
within 60 days of the injection. Intraocular pressure
asymmetry between the eyes by a value of more than
3mm Hg was also considered. Those with a history of
glaucoma or elevated IOP in the past did not qualify to
participate. “A total of 11,828 bevacizumab injections and
10,354 ranibizumab injections were administered during
the study period at the two clinical sites. In this series, 21
eyes of 18 patients developed elevated IOP of 24mm Hg
of higher within 60 days of previous injection” (Pershing
et al., 2013). Most patients were Caucasian females who
received treatment for wet AMD and presented other
pathology related to elevated IOP, such as narrow anterior chamber angles on gonioscopy. Most of the 21 eyes
needed treatment for elevated pressure, 76% required
prolonged treatment, and 19% resolved with no treatment. It was found that a risk of increase in IOP persisted
even later in treatment after multiple injections to the
eye. This risk was reported regardless of the subclass of
anti-VEGF used, however a higher chance of IOP elevation in ranibizumab treatment was reported (Pershing et
al., 2013). This risk is especially important to consider if
the patient in question has glaucoma or is a glaucoma
suspect, as a subtle rise in intraocular pressure may be
detrimental. In such a case, the drug should be administered and the patient carefully monitored for changes in
IOP that may lead to an acute attack of glaucoma.
Additionally, receiving anti-VEGF drugs alongside having
coexisting cardiovascular conditions may lead to adverse
effects. The SUSTAIN trial showed that although there is
no link to myocardial infarction, a 10% incidence of stroke
was found in patients with previous cerebrovascular disease that were also being treated with VEGF inhibiting
medications (Stewart, 2012). In patients receiving regular
treatment with ranibizumab, there was a higher incidence
of heart attack, stroke, or death from cardiovascular or
unknown conditions (Wells, 2016).
Finally, the nature of this treatment option for AMD/
DMR is that frequent, monthly follow up visits are required to monitor and readminister the drug, rendering compliance of treatment more difficult to upkeep.
Inherent drawbacks to the use of VEGF inhibiting agents
are its cost and frequency of treatment as it relates to
burden on the patient. Perhaps lowering the overall cost
of the treatment (medication and visit) while creating a
medication with a longer half-life or efficacy will allow
more patients to undergo long term treatment, preventing blindness (Baek et al., 2019). In some cases, the use
of a laser to clear drusen and prevent the furthering of

neovascularization may be more appropriate, as will now
be discussed.
Use of Pan Retinal Photocoagulation
Although traditional cases of diabetic retinopathy and
macular degeneration now indicate treatment with intravitreal injections, this has not been the case for long.
In the past, the first line of defense was treatment with
blue-green Argon laser in order to create lesions around
the area of retinal neovascularization and promote the
regression of abnormal blood vessels and drusen. This
option to help DMR and AMD is called pan retinal photocoagulation. In this technique, a beam of light from the
laser is focused onto the retina using a special lens. The
strength of the laser now used is usually weaker, with
studies trying to determine the efficacy of subthreshold
laser treatment to avoid applying more energy than necessary. Up to 300 lesion spots may be delivered, with each
one between 100µm and 200µm in size. “Subthreshold
photocoagulation delivers light energy with very short
impulses that are absorbed by the RPE only, aiming to
spare the neurosensory retina”. Adjusting the strength,
pulse duration, and frequency of the laser makes the
treatment effective yet more gentle on the choroid in
an attempt to reduce potential photoreceptor loss.
Although the mechanism of treatment is not fully known,
some ideas explain its efficiency.
Firstly, the laser may help in clearing remnants left by
phagocytic cells and macrophages along the choroid. It is
hypothesized that the accumulation of these cells leads
to the development of drusen. Another train of thought
is that the laser may precipitate the RPE layer to release
cytokines and growth factors that are able to “modify the
biochemical processes underlying the clinical manifestations of the retinal disorder, rather than simply destroying
drusen, and may also act on the drusen remote from the
site of laser energy application” (Virgili et al., 2015). Also,
the laser energy is capable of causing the temperature of
the retina to rise slightly, leading to the release of heat
shock proteins.They “act as chaperones for refolding misfolded proteins in aging cells, thereby rejuvenating retinal
pigment epithelium (RPE) cells and restoring their cellular
function” (Eng et al., 2019).
A study included patients with extrafoveal neovascular
presentation with drusen. Patients were 50 years of age
or older and visual acuity either was 20/100 or worse
(Silva, 2011). The laser used was a conventional bluegreen Argon laser. Energy was set to be powerful enough
to create the necessary lesions or controlled burns on
neovascular areas. In this study, attention was not paid
to maintaining sub-threshold energy. By using pan retinal
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photocoagulation, the likelihood to stabilize the visual
acuity of a patient doubled for those eyes, showing a 58%
reduction in the risk to have severe vision loss.
Highlights from the Macular Photocoagulation Study
Group (Silva, 2011) are shown here:
A. Five years after treatment, average visual acuity
was 20/125 in the group treated compared to
20/200 in patients not treated with PRP.
B. Within the five-year span of treatment, 54% of
patients had signs of recurring severe vision loss,
with the majority of cases taking place within two
years of treatment.
C. Smoking after PRP treatment was linked to accelerated recurrence of severe vision loss, as 85% of
patients smoked more than 10 cigarettes per day
compared to 51% in the non-smoking population.
An additional analysis of 12 studies of 2,481 eyes that
were treated with subthreshold pan retinal photocoagulation showed similar results. This study included treatments done with 514nm and 810nm lasers. Conclusions
of the review showed that pan retinal photocoagulation
treatment is effective in reducing drusen count and
thereby improving visual acuity in patients with dry AMD
with the 810nm laser being consistently more effective.
However, the study mentions that in order to obtain a
significant improvement in visual acuity, the treatment
must clear a substantial amount of drusen. Additionally,
the study found that among the eyes that were treated,
there was “no significant change in the risk of developing choroidal neovascularization or geographic atrophy”
(Eng et al., 2019) and that more research would need
to be done to conclusively confirm the efficacy of the
810nm infrared diode laser compared to the 514nm laser.
Comparing the treated patients with the observed
patients in the study, the following data was obtained in
regard to the relationship of diminishing drusen and treatment with pan retinal photocoagulation (Eng et al., 2019):
1. In five out of the 12 studies in which visual acuity
was measured, it was determined that there was
no difference in visual acuity in the groups who
had and had not received treatment. Yet, the remaining studies showed a correlation between
receiving treatment and improved visual acuity.
This indicates that although pan retinal photocoagulation may be effective in clearing drusen from
the retina, perhaps more research is necessary to
conclude the effectiveness of the laser in improving the visual outcome for the patient.
2. In regard to the development of choroidal neovascularization (CNV), three of nine studies that
followed up on this mentioned that there was no
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development of CNV. An additional three however noted that eyes treated with subthreshold pan
retinal photocoagulation were slightly more likely
to develop CNV.
3. Geographic atrophy was also monitored in this
series of studies. It was reported that two studies
showed GA in treated eyes, while another study
showed that although the incidence of developing
geographic atrophy in treated eyes was 3.9%, the
likelihood was higher in eyes that were not treated, at 14.0%.
After five years, following up on patients showed 64%
of eyes that were not treated with the laser developed
more severe vision loss compared to 46% of patients that
had treatment with PRP.Yet, the recurrence rate of vision
loss was 54%, with 75% of those recurrences taking place
in the first year (Cook et al., 2008).
Conclusion
Currently, there are a number of available treatment
options to reduce visual complaints and pathological
findings in patients with chorioretinal vascular conditions. Interventions such as subthreshold pan retinal
photocoagulation and vascular endothelial growth factor
inhibiting agents are still undergoing various studies, yet
they do appear to be effective and promising options for
patients battling age related macular degeneration and
diabetic retinopathy. There are reasons why a clinician
may choose one over the other in hopes of achieving
the maximum benefit for the patient, depending on cost,
compliance, and coexisting conditions. Although vascular
endothelial growth factor inhibiting agents have become
the first line of defense against neovascularization and
other such complications of ocular disease, there are still
reasons why they may not be the appropriate treatment
option for a given patient as there are associated risks.
Furthermore, some clinicians believe that using alternatives such as PRP may be a better option altogether. On
the other hand, an advantage of VEGF inhibiting agents
over pan retinal photocoagulation is “prompt regression
of neovascularization and the preservation of peripheral
and night vision” (Buffolino & Park, 2019). Undergoing
treatment with VEGF inhibiting medications for patients
with severe vision loss may not be recommended as the
drug may not be able to restore vision (Baek et al., 2019),
however in most circumstances,VEGF inhibiting drugs can
and perhaps should be implemented to alleviate both the
visual complaints and the pathological dangers associated with chorioretinal vascular conditions. Potential risks
previously discussed such as IOP elevation, inflammation,
visual and pathological damage, and coexisting conditions
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may need to be considered on a case by case basis, necessitating another modality of treatment. Nevertheless,
it should be stressed that without a proper dilated exam,
very little can be observed and treated; imaging methods
can also be used to monitor the stability or progression
of these diseases.
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